Camras Vision just completed a $5.7 million funding round, and it intends to raise another $15 million next year. The company is attempting to shepherd the Camras shunt through the U.S. Food and Drug Administration approval process, after which the business will probably be sold. The Camras shunt was invented by the late Carl Camras and his daughter Lucinda. Carl, celebrated for his ophthalmological research, was one of the inventors of Latanoprost, a pharmaceutical treatment for glaucoma. Glaucoma is a leading cause of irreversible blindness expected to affect 80 million worldwide by 2020. It is treated by reducing pressure in the eye, but to date there has been no way to “dial up” a treatment to adjust pressure to a target value. As a result, 10% of patients lose vision following glaucoma treatments. The shunt addresses this problem by draining as much fluid as is necessary out of the aqueous humor. Results from the first clinical study, begun in 2016 in the Philippines, have been “encouraging,” and the next in-human trial will begin in the Dominican Republic in 2019. Studies following that will be performed in Europe and the United States.